Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06705075 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE
A Phase 2 study of Uterine Fibroid, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06705075: Recruiting Phase 2 study of Uterine Fibroid, sponsored by Thomas Jefferson University.
NCT06705075 is a Phase 2 study of Uterine Fibroid that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 80 participants, below the 306-participant average among 5 other Uterine Fibroid trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06705075, a Phase 2 study of Uterine Fibroid, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study goals are to determine the patterns of uterine fibroid vascularity pre and post UAE using CEUS resulting in an alternative to gadolinium-enhanced MRI that is less expensive, has less contra-indications and side effects, is real time, and noninvasive helping physicians to evaluate the result of UAE procedures. Also, this study will evaluate uterine fibroid pressures using SHAPE, comparing the results with normal myometrium tissue in order to determine its characteristics and tissue differences, which we believe will lead to the development of a new biomarker for the diagnosis and treatment of uterine fibroids.
Primary Outcome
This is an open-label, non-randomized, single center, clinical study that will be conducted at TJU. This trial of CEUS and SHAPE imaging examinations will evaluate the microvascularity of uterine fibroids in order to determine vascularity characteristics before,2 weeks, as well as 3 months after UAE to assess the success of the UAE procedure in short term follow-up.
Conditions Studied
Interventions
- DRUG Perfluten
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
What NCT06705075 shows while recruiting
NCT06705075 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 306-participant average among 5 other Uterine Fibroid trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Uterine Fibroid appearing as the primary indexed condition, and to 1 intervention - of which Perfluten is the first listed.
NCT06705075 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06705075 about?
NCT06705075 is a clinical study titled "Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE". This study goals are to determine the patterns of uterine fibroid vascularity pre and post UAE using CEUS resulting in an alternative to gadolinium-enhanced MRI that is less expensive, has less contra-indications and side effects, is real time, and noninvasive helping physicians to evaluate the resu...
What is the current status of trial NCT06705075?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-01-27. Estimated completion is 2026-09-30.
What conditions does trial NCT06705075 study?
This clinical trial studies the following conditions: Uterine Fibroid.
What interventions are being tested in trial NCT06705075?
The interventions under investigation include: Perfluten (DRUG).
Who is sponsoring clinical trial NCT06705075?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06705075 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Fibroid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids
RECRUITING
-
Life Study: Lifestyle Intervention in Fibroid Elimination
ACTIVE NOT RECRUITING · NA
-
Implementation of Uterine Fibroid Option Grid Patient Decision Aids Across Five Organizational Settings
COMPLETED · NA
-
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
COMPLETED · Phase 3
-
An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI